Bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: Results of a randomized phase III trial. - Hurwitz,H.; Fehrenbacher,L.; Novotny,W.; Cartwright,T.; Hainsworth,J.; Heim,W.; Berlin,J.; Baron,A.; Griffing,S.; Holmgren,E.; Ferrara,N.; Fyfe,G.; et al. (N Engl J Med, 2004)